Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis

系统性硬化症皮肤、肺和血管并发症的临床转化研究

基本信息

批准号：
10705585
负责人：
ROBERT A. LAFYATIS
金额：
$ 156.58万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-20 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10705585
关键词：
Affect Animal Model Autoimmune Diseases Automobile Driving Binding Sites Bioinformatics Biological Biological Markers Biological Models Biology Biopsy Blood Blood Platelets Blood Vessels Cell Communication Cell Energetics Cells Center for Translational Science Activities Childhood Chromatin Clinical Clinical Data Clinical Trials Complement Connective Tissue Cutaneous sclerosis Data Data Set Databases Development Disease Disease Marker Disease Pathway Epigenetic Process Fibroblasts Fibrosis Gene Expression Genomics Glutaminase Glutamine Goals Heterogeneity In Vitro Interleukin-6 Interstitial Lung Diseases Lead Localized scleroderma Lung Lung Transplantation Lung diseases Macrophage Mediating Mediator Medical center Metabolic Metabolism Modeling Molecular Multiomic Data Myofibroblast Observational Study Organ Oxidative Phosphorylation PIK3CG gene Pathogenesis Pathogenicity Pathologic Processes Pathway interactions Patients Perfusion Pharmaceutical Preparations Phenotype Population Positioning Attribute Positron-Emission Tomography Process Proteomics Protocols documentation Pulmonary Fibrosis Research Personnel Resources Rheumatology Role Sclerosis Serum Markers Skin Skin Tissue Slice Structure of parenchyma of lung Systemic Scleroderma Systems Biology Talents Technology Testing Tissues Translational Research Universities Vacuolar Protein Sorting biobank bioinformatics tool cell type clinical translation collaborative environment cytokine data integration detection method drug discovery epigenomics experience gene discovery genetic regulatory protein genomic data human disease human tissue imaging approach inhibitor innovation medical schools multiple omics new therapeutic target novel novel marker novel therapeutics preclinical study profibrotic fibroblast programs protein expression pulmonary arterial hypertension repository single cell technology single nucleus RNA-sequencing single-cell RNA sequencing skin disorder specific biomarkers targeted treatment therapeutic target tool transcription factor transcriptome transcriptomics translational study vascular injury

项目摘要

The overall goal of this Center of Research Translation is to utilize biomarker tools and other translational research observations to discover new therapies for patients with systemic sclerosis (SSc). This goal can be broken down into four intermediate objectives: understanding pathogenic pathways through translational studies, identifying informative biomarkers for SSc complications, applying bioinformatics and systems biology approaches to interpret translational and biomarker data, and developing novel targeted therapeutics. Among current obstacles to progress in finding new drugs for SSc patients is the continuing limited understanding of SSc pathogenesis, in part due to its complexity and heterogeneity, and in part due to the lack of good animal models. The University of Pittsburgh School of Medicine stands in a unique position for informative translational studies into SSc due to special resources and intellectual talent. It has very large, longitudinal clinical-biological SSc repositories in rheumatology and pulmonary divisions; it has the only large national experience in single cell studies in both SSc skin and lungs; it has a strong experience in studying lung proteomics; it has pulmonary experts in modeling lung disease using in vitro precision cut lung slices and ex vivo lung perfusion; it has a highly sophisticated program studying pediatric localized scleroderma, as well as pediatric SSc; it has an experienced and innovative systems biology group; and it has a vigorous drug discovery platform. In Project 1 investigators will expand preliminary observations using single cell RNA-seq, to understand the transcription factors (TFs) associated with myofibroblast differentiation and discover latent factors/cytokine mediating macrophage-fibroblast interaction in SSc and pediatric LS. In Project 2 investigators will examine the genomic and proteomic landscape of patients with SSc-associated interstitial lung disease. Project 2 will also screen and carry out preclinical studies of Smad3 translocation inhibitors using precision cut lung slices. In Project 3 investigators will study altered platelet energetics and utilize 18F-fluoroglutamine PET imaging to understand the role of metabolic reprogramming and glutaminolysis in SSc-associated pulmonary arterial hypertension. Project aims will be supported by two resource cores: a Clinical and Biospecimen Core and a Systems Biology Core. The former will include collecting comprehensive clinical data, acquiring skin biopsies and lung explant tissue, and preparing precision cut lung slices. The latter will use a broad range of bioinformatics tools, including novel methods for detecting stereospecific TF binding sites, and for discovering latent factors mediating cell- cell interactions in scRNA-seq/multiome datasets. The Systems Biology Core will also synthesize proteomic and genomic data in project 2, and integrate data from each project and across projects to develop models for common molecular pathways associated with different disease manifestations. The focus of each of the projects on different SSc clinical manifestations, mediators of disease, and drug inhibitors will provide a rich, highly collaborative environment for fundamental discovery within bridging project topics and core resources.

该研究中心翻译的总体目标是利用生物标志物工具和其他翻译研究发现系统性硬化症患者（SSC）的新疗法的研究观察结果。这个目标可以是分解为四个中间目标：通过翻译研究了解致病途径，识别用于SSC并发症的信息性生物标志物，应用生物信息学和系统生物学解释翻译和生物标志物数据并开发新颖的靶向治疗剂的方法。之中目前为SSC患者寻找新药的进展障碍是对 SSC发病机理，部分是由于其复杂性和异质性，部分原因是缺乏良好的动物型号。匹兹堡大学医学院处于独特的地位，以提供丰富的翻译由于特殊的资源和知识才能，研究SSC。它具有非常大的纵向临床生物学风湿病学和肺部分裂的SSC存储库；它具有单一的唯一大型国家经验 SSC皮肤和肺部的细胞研究；它在研究肺蛋白质组学方面具有丰富的经验。它有肺部使用体外精确切割的肺切片和离体肺灌注来建模肺部疾病的专家；它有一个高度精致的计划研究小儿局部硬皮病以及小儿SSC；它有一个经验丰富的创新系统生物学小组；它具有一个有力的药物发现平台。在项目1中研究人员将使用单细胞RNA-seq扩大初步观察，以了解转录因子（TF）与肌纤维细胞分化相关并发现潜在因子/细胞因子介导 SSC和小儿LS中的巨噬细胞纤维细胞相互作用。在项目2中，研究人员将检查基因组和与SSC相关的间质肺疾病患者的蛋白质组学景观。项目2也将筛选并使用精确切割的肺切片对SMAD3易位抑制剂进行临床前研究。在项目3中研究人员将研究改变血小板能量学并利用18F-氟他透明宠物成像来理解代谢重编程和谷氨酰胺溶解在SSC相关肺动脉高压中的作用。项目目标将得到两个资源核心的支持：临床和生物循环核心和系统生物学核。前者将包括收集全面的临床数据，获取皮肤活检和肺epplant 组织，并准备精确切割的肺切片。后者将使用广泛的生物信息学工具，包括检测立体特异性TF结合位点的新方法，以及发现介导细胞的潜在因素 SCRNA-SEQ/MultioMe数据集中的细胞相互作用。系统生物学核心还将合成蛋白质组学项目2中的基因组数据，并整合每个项目和跨项目的数据，以开发模型与不同疾病表现相关的常见分子途径。每个的重点关于不同SSC临床表现，疾病介质和药物抑制剂的项目将提供丰富的，在桥接项目主题和核心资源中基本发现的高度协作环境。

项目成果

期刊论文数量（1）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Loss of Protein Kinase D2 Activity Protects Against Bleomycin-Induced Dermal Fibrosis in Mice.

DOI：
10.1016/j.labinv.2022.100018
发表时间：
2023-02
期刊：
LABORATORY INVESTIGATION
影响因子：
5
作者：
Chen, Liping;Zhao, Jinjun;Chao, Yapeng;Roy, Adhiraj;Guo, Wenjing;Qian, Jiabi;Xu, Wanfu;Domsic, Robyn T.;Lafyatis, Robert;Lu, Binfeng;Deng, Fan;Wang, Q. Jane
通讯作者：
Wang, Q. Jane